Physiomics Announces License Agreement with Eli Lilly

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a license agreement with Eli Lilly and Company (‘Lilly’) (NYSE: LLY), the global pharmaceutical company. Under the terms of the agreement, Physiomics will license to Lilly a customised version of its “ModelPlayer” for in silico simulations of unspecified anticancer drugs and Lilly will have the option to purchase
additional licenses.

Physiomics’ “ModelPlayer” is a stand-alone simulation platform used for in-house model development that can be out-licensed to partners to allow them to perform their own simulations using Physiomics’ models. It incorporates a range of features necessary for developing and calibrating models and simulating anticancer drugs.

Dr Christophe Chassagnole, COO of Physiomics, said:
‘We are delighted with the continued interest shown by Lilly in Physiomics’ technology. We hope that the capability for Lilly scientists to directly use Physiomics’ models will strengthen the quality of the interactions within our ongoing research collaborations. This is also an important commercial and technical milestone for Physiomics as this is the first time that we have out-licensed our technology.’